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Abstract Proinflammatory cytokines and secretory
phospholipase A2 (sPLA2) are elevated in patients
with inflammatory bowel disease (IBD). We previously
reported that the proinflammatory cytokine IL-6
increased the expression of sPLA2 (a hydrolyzer of
phosphatidylcholine) and decreased membrane integrity
in an intestinal epithelial cell culture model. To deter-
mine the physiological effects of the IL-6 mediated
increase in sPLA2 on decreased epithelial layer integ-
rity, we investigated alterations of intracellular/secre-
tory phospholipid (PL) composition in a cell culture
model. In addition, since other PLs may also mediate
epithelial membrane activity, we investigated the effect
of IL-6 on PL activity in a Caco-2 enterocyte culture
model. Caco-2 cells were incubated for 72 h with IL-6
or media alone (control). Both media and cell lysate
were analyzed for PL composition using thin-layer
chromatography. The PL composition in the media did
not show any differences between the two groups
(p>0.1). Total intracellular PL contents were also un-
changed; however, IL-6 led to significant changes in PL
composition including an increase in phosphatidyleth-
anolamine (PE) and sphingomyelin (SM) and a decrease
in phosphatidylcholine (PC) and lysophosphatidylcho-
line (LPC) (p<0.05). Both PE and SM are known as
inflammatory signaling factors involved in human IBD.
Our study suggests that the decreased membrane
integrity seen with IL-6 application may occur via
intracellular PL alterations, rather than through the
direct effects of sPLA2.
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Introduction
Elevated proinflammatory cytokine levels are present
in patients with inflammatory bowel disease (IBD)
[1, 2, 3]. In particular, the stimulated inflammatory
cytokine interleukin-6 (IL-6) seems to play an impor-
tant role in maintenance of immune suppression in
septic patients [4, 5]. In a human intestinal epithelial
cell culture model, IL-6 has been shown to mediate a
selective down-regulation of enterocyte membrane
hydrolase, which normally protects the intestinal bar-
rier function [6, 7]. Another mediator elevated in septic
shock is secretory phospholipase A2 (sPLA2), which is
a major enzyme produced in response to proinflam-
matory cytokines and is found in inflammatory fluids
as well as in the serum of patients suffering from septic
shock [8, 9].
The presence of sPLA2 may have significant
physiological influence. It has been reported that the
PLA2 hydrolysis product of phosphatidylcholine (PC),
lysophosphatidylcholine (L-PC), causes a loss of epi-
thelial barrier integrity in both rat models [10, 11] and
an enterocyte cell culture model [12]. We have previ-
ously shown that the proinflammatory cytokine IL-6
increases sPLA2 concentrations and decreases cellular
membrane integrity in an intestinal epithelial cell
culture model (presented at the 14th International
Symposium on Pediatric Surgical Research, 2001,
Madrid); however, the specific physiological effect of
increased sPLA2 secretion in this model is unknown.
To determine the physiological effects of the IL-6
mediated increase in sPLA2 on decreased epithelial
layer integrity, we investigated alterations of intracel-
lular/secretory phospholipid (PL) composition in this
cell culture model.
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Human enterocyte Caco-2 cell line (no. HTB37) were obtained
from the American Type Culture Collection (Manassas, Va.).
Caco-2 cell line passages 26–35 were grown in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum (Fisher, Pittsburgh, Pa.), 1% non-essential amino acids
(Gibco, Grand Island, NY), 1% sodium pyruvate (Fisher, Pitts-
burgh, Pa.), penicillin G (100 U/ml), and streptomycin (100 g/ml;
Fisher, Pittsburgh, Pa.), in a 5% CO2 atmosphere at 37C. After
reaching 60–70% confluence, cells were harvested by trypsinization
with trypsin-EDTA (Gibco, Grand Island, N.Y.), washed and
resuspended in DMEM. Caco-2 cells were seeded onto two types of
cell culture plates at a density of 1·105 cells per well; one was a
3-cm diameter cell culture dish and the other Transwell cell culture
inserts with 0.33-cm2-sized porous filters (pore size 0.3 lm), coated
with 1.0 mg/ml rat-tail type-I collagen (Sigma, St. Louis, Mo.) in a
two-chamber cell culture system (Costar, Cambridge, Mass.).
Caco-2 cells were then grown for 14 days in media to allow them to
reach confluence and fully differentiate. Media were changed every
second day. Cell monolayers were used after a TEER of over
200 ohm/cm2 was measured in the 0.33-cm2-sized filters.
Experimental models
Well-differentiated Caco-2 cell monolayers in Transwell cell culture
systems were used for investigating the effect of cytokine IL-6 (US
Biological, www.usbio.net) on epithelial integrity by measuring
transepithelial electrical resistance (TEER) and mannitol paracel-
lular permeability. The cell monolayers were then incubated with
media or media with the cytokine IL-6 (10 ng/ml) in the basal
chamber for 72 h.
Transepithelial electrical resistance (TEER) was measured be-
fore and 72 h after cytokine treatment using an epithelial volt
ohmmeter (EVOM; World Precision Instruments, Sarasota, Fla.).
The TEER values obtained in the absence of cells were used as
background, and resistance was expressed as ohm · square centi-
meters (ohm cm2). Media samples from the apical and basal
chambers were then collected for total sPLA2 activity and phos-
pholipid concentration.
3H-Mannitol was used as another measure of cellular mono-
layer integrity. After 72 h incubation with media, or media with
IL-6, the monolayers were washed with media and then 3H-man-
nitol (molecular formula weight 182.2) was administrated into the
apical chamber for investigating permeability. After 2 h incubation
with 3H-mannitol at room temperature or at 4C, the media in the
basal chamber was collected and measured for the presence of 3H-
mannitol. The data are expressed as percent ratio of tritium in the
basal chamber / (tritium in basal chamber + the tritium in apical
chamber) · 100. Another measuring tool to assess paracellular
permeability, Dextran Blue (DB; molecular weight 2,000,000) was
also used. After 72 h of incubation with media or media with IL-6,
the monolayers were washed by media and then DB was admin-
istered into the apical chamber. After 2 h of incubation with DB,
the media in the basal chamber was collected and measured using a
spectrophotometer at 620 nm. The DB concentrations were deter-
mined following comparisons with a standard curve of DB.
Human synovial SPLA2 secreted into the media was measured
by Enzyme Immunoassay (ELISA) kit (Cayman Chemical, Ann
Arbor, Mich.). Media samples were collected, centrifuged, and the
supernatants were stored at )80C. All samples were analyzed
according to the manufacturer’s instructions. Briefly, 100 ll of
diluted samples were applied in duplicate to each well of a 96 well
plate coated with a monoclonal antibody specific for sPLA2.
Next, 100 ll of acetylcholinesterase: Fab’ Conjugate (AchE:
Fab’), which binds selectively to a different epitope on the sPLA2
molecule, was added to the wells and incubated overnight at 4C.
All solutions from the wells were removed, and the wells were
rinsed six times with a wash buffer, followed by the addition of
200 ll of Ellmen’s Reagent and allowed to incubate 3 h in the
dark at room temperature. The absorbance was read at 420 nm
using model 550 Microplate Reader (Bio-Rad, Hercules, Calif.)
and the results were compared with a standard curve of sPLA2.
Phospholipid composition of the media and cell lysates was
measured after 72 h of incubation with media or media with IL-6.
Four-milliliter media samples were collected and immediately
frozen and stored at )70C until assayed. The cell monolayers
were harvested by trypsinization with trypsin-EDTA and the cell
lysate was immediately frozen and stored at )70C until assayed.
Total lipids were extracted using a chloroform/methanol method
[13]. Lipid extracts were dried under nitrogen gas, dissolved in
chloroform and the total phospholipid content determined as
phospholipid phosphorus [14, 15]. Extracted total phospholipids
were separated by thin-layer chromatography (TLC) on silica gel
60 plates using chloroform/methanol/acetic acid/water
(60:18:21:1.8). Plates with individual phospholipids were placed in
8% (wt./vol.) CuSO4 phentahydrate in water/methanol/concen-
tration H3PO4 (60:32:8) or 0.1% (wt./vol.). Ninhydrin in ethanol
was used for visualization after autoclaving (150C, 15 min,
110C, 10 min, respectively). The TLC plates were scanned and
the individual PL’s band images were then quantified using an
imaging computer program Kodak EDAS 290 system (Kodak,
Rochester, N.Y.). Individual phospholipid concentrations were
compared with the following phospholipids; egg-yolk PC or
lysophospholipid; LPC (Sigma) which functioned as standards.
The percent of phosphatidylcholine from the chromatographic
analysis was used to calculate the total PC content in the lipid
extract. The results are reported as phosphatidylcholine phos-
phorus/milliliters of media and phosphatidylcholine phosphorus/
total amount of phosphate (mol.) of cells obtained from the
epithelial monolayer.
Statistical analysis
Results are expressed as mean±SD. Statistical analysis was per-
formed using linear regression analysis and one-way analysis of
variance, with P<0.05 considered significant.
Results
The cytokine IL-6 caused a significant decrease in
TEER (135±29 ohm cm2) compared with controls
(337±0.1 ohm cm2; P<0.05; Fig. 1).
IL-6 also caused a significant increase in Ma-Pm at
both room temperature and at 4C (1.23±0.27 and
0.50±0.06%, respectively) compared with controls
(0.42±0.04 and 0.14±0.03%, respectively; P<0.05;
Fig. 2); however, DB permeability following IL-6
administration did not change compared with controls.
Secretion of sPLA2 is shown in Fig. 3. IL-6 led
to a significant increase in total sPLA2 secretion
(143.8±12 ng sPLA2/mg DNA) compared with controls
(34.4±2.8 ng sPLA2/mg DNA; P<0.05).
There were no differences in total media PL compo-
sition between the two groups (p>0.1). Total intracel-
lular PL contents were also unchanged; however, percent
ratios of specific PLs were altered after IL-6 treatment
(Fig. 4). IL-6 led to significant changes in PL composi-
tion, including an increase in PE (9.6%) and SM (5.7%)




Cytokines, specifically IL-6, have been shown to be in-
creased in patients with IBD [1, 2, 3, 16]. Moreover, IBD
patients are more prone to develop bacterial transloca-
tion (BT), which may be related to increased intestinal
epithelial permeability. Phospholipases have been rec-
ognized as a major enzyme group which have a critical
role in diverse cellular responses, including phospholipid
digestion and metabolism, host defense and signal
transduction [17]. Secretory PLA2 and cytosolic PLA2
(cPLA2) have different functions; sPLA2 appears to be a
key factor in the inflammatory process [17], whereas
cPLA2 functions mainly as a cell signaling factor [18].
Increased sPLA2 is found in inflammatory fluids as well
as in the serum of patients with rheumatoid arthritis [19],
septic shock [8, 9], and IBD [20, 21, 22]. The expression
of sPLA2 is increased in a variety of mammalian tissues,
and is also increased in cancer patients [23]. The sPLA2
is understood to be correlated with cell growth, as
demonstrated in an in vitro model of epithelial injury, in
which sPLA2, in a dose-dependent manner, stimulated
rat intestinal epithelial cells (IEC-6) to migrate [24].
Other studies in murine intestinal cells have shown that
sPLA2 inhibitors prevented the growth of malignant
cells [25]. In our preliminary study, sPLA2 secretion
showed a linear rise (r=0.89) with increasing cell num-
bers, which suggests that sPLA2 may have a role in
growth or stabilization of cells under normal conditions
(presented at the 14th International Symposium on
Pediatric Surgical Research, 2001, Madrid).
Cytokine administration shows a close correlation
with sPLA2 secretion and leads to a reduction in TEER.
Recombinant human IL-6 can increase serum concen-
trations of sPLA2 in humans [26]. Crowl et al. showed
that IL-6 led to an up-regulation of sPLA2 gene
expression in human hepatoma cells [27].
We hypothesized at the initiation of this study that
high levels of the cytokine IL-6, as seen in IBD, would
stimulate the secretion of sPLA2, resulting in epithelial
barrier function breakdown through the increased LPC
produced by sPLA2. In our study, we showed that IL-6
led to both a decline in TEER and an increase in
Ma-Pm, suggesting that epithelial barrier function is
decreased. In addition, we showed increased sPLA2
secretion in the IL-6 treated epithelial cell culture
model. Based on these findings, we hypothesized that
the increased sPLA2 would correlate with increased
LPC products or alteration of secreted PLs in the
media; however, the levels of PLs secreted into the
Fig. 2 Effect of IL-6 treatment on 3H-mannitol permeability at
room temperature and at 4C. Asterisk Significant difference
between controls and IL-6 treatment group, P<0.05. Open columns
control group, solid column IL-6 group
Fig. 3 sPLA2 secretion after 72 h of IL-6 treatment measured by
ELISA. Asterisk Significant difference between controls and IL-6
treatment group, P<0.05. Open column control group, solid column
IL-6 group
Fig. 1 Alteration of transepithelial electrical resistance (TEER)
between pre- and post-treatment with media (control group) or
media with IL-6 (IL-6 group). Asterisk Significant difference
between controls and IL-6 treatment group, P<0.05. Open columns
control group, solid column IL-6 group
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media were unchanged compared with controls. It is
possible that secreted sPLA2 as induced by IL-6 might
have another action which induces the loss of epithelial
membrane integrity. One such possibility is an alter-
ation in the formation of intracellular lipid content, as
it has been shown that sPLA2 can promote cholesterol
absorption [28].
On the other hand, it was interesting to note that
intracellular PLs were significantly altered following IL-
6 treatment in this model. These changes consisted of
increased PE and SM and a decrease in PC and LPC.
The PE and SM have been identified as signaling mol-
ecules in cellular apoptosis [29, 30, 31]. In our model,
apoptotic changes were not evident at 72 h following
Il-6 treatment (data not shown).
An increase in IL-6 caused by an inflammatory pro-
cess in the intestine might have the following physio-
logical effects: one is increased permeability caused by
decreased epithelial cell membrane resistance and in-
creased uptake of antigens through paracellular routes
or by active transport. Secondly, increased IL-6 pro-
duction may stimulate increased sPLA2 secretion into
the intestinal lumen, which then leads to secondary
epithelial membrane breakdown. Thirdly, increased IL-6
secretion may increase the intracellular PL’s PE and SM
which function as signaling compounds for either
inflammation or apoptosis.
Conclusion
In conclusion, this study demonstrates that IL-6 medi-
ates sPLA2 secretion and causes a decrease in epithelial
integrity as measured by TEER and Ma-PM; however,
the increased sPLA2 produced by IL-6 treatment does
not lead to increased LPC concentrations. On the other
hand, IL-6 secretion leads to significant alterations in
phospholipid content including intracellular phosphati-
dylethanolamine and sphingomyelin. It is possible that
there may be a relationship between the increased sPLA2
produced by IL-6 treatment and alteration in intracel-
lular PL composition. Further investigation is needed,
however, to better understand this mechanism. These
facts might help us to understand the mechanisms in-
volved in the loss of epithelial permeability in IBD
patients and its relationship to increased cytokine pro-
duction, especially IL-6.
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